About Us
We are a clinical-stage biotech company advancing novel oncolytic immunotherapies intended to ignite a systemic immune response and potentially treat a abroad range of difficult-to-treat cancers.
Our Mission
We imagine a world where cancer is a curable disease. Replimune's mission is to revolutionize cancer treatment through comprehensive activation of a tumor-specific immune response — potentially treating a broad range of cancer types.
Driven by our commitment to patients
We are united in our purpose of boldly reshaping cancer care because patients’ lives depend on it. We value our people, innovate in a collaborative and friendly environment, reward dedication and performance, and take pride in the meaningful work that we do.
Our Story
Since 2015 we’ve been pushing for the breakthrough that changes what a cancer diagnosis means to patients.
Founded in 2015 by industry-leading oncolytic immunotherapy experts, we are focused on transforming the future of immunotherapy. In just 10 years, Replimune has moved from the lab to a new potential treatment option for patients, pending FDA approval.
State-of-the-art manufacturing
Our own 63,000 square foot U.S. manufacturing facility enabling global commercial supply.
A broad set of clinical programs
Multiple clinical trials exploring the RPx platform in a variety of oncology indications.
Strong IP position
Wholly-owned, unencumbered assets/RPx platform.
We are proud to support the work of these organizations
Looking for a new career opportunity?
Replimune is looking for motivated, talented individuals to join our team as we work to transform the future of cancer treatment and make a difference for patients.